Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from UltraGreen.ai Limited ( (SG:ULG) ).
UltraGreen.ai has secured regulatory approvals for its IC-Flow Imaging System V2 in India, Thailand, the Philippines, and Bangladesh, expanding the device’s global footprint to 45 territories. The hand-held near-infrared fluorescence imaging system supports intraoperative visualisation in plastic and micro-reconstructive surgery, organ transplants, and lymphatic mapping, allowing the company to commercialise the product in these key South and Southeast Asian markets.
Executives said the new clearances strengthen UltraGreen’s ability to deepen partnerships with hospitals, distributors, and clinical educators while ensuring alignment with local regulatory standards. Building on recent approvals for its Verdye pharmaceutical product in the Philippines and IC-Flow V2 in Malaysia, the move further consolidates UltraGreen’s regulatory and commercial position across APAC healthcare systems.
The most recent analyst rating on (SG:ULG) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on UltraGreen.ai Limited stock, see the SG:ULG Stock Forecast page.
More about UltraGreen.ai Limited
UltraGreen.ai Limited is a Singapore-listed provider of fluorescence-guided surgery and digital health solutions, specialising in near-infrared imaging platforms that support intraoperative visualisation. The company focuses on expanding access to its technologies across global healthcare markets, with a growing emphasis on the Asia-Pacific region.
Average Trading Volume: 2,005,735
For an in-depth examination of ULG stock, go to TipRanks’ Overview page.